Last reviewed · How we verify
NCT06006819
Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease
trial in Chronic Kidney Diseases in 155 participants. Currently enrolling.
23 December 2025
Quick facts
| Lead sponsor | Cheng-Hsin General Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 155 |
| Start date | 1 January 2023 |
| Primary completion | 23 December 2025 |
| Estimated completion | 23 December 2025 |
| Sites | 1 location across Taiwan |
Conditions studied
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
- Acute Heart Failure — all drugs for Acute Heart Failure →
- Biomarker — all drugs for Biomarker →
Sponsor
Cheng-Hsin General Hospital
Who can join
Adults 20 to 90, any sex, with Chronic Kidney Diseases or Acute Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06006819
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Diseases
Currently open trials in the same condition.
- NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
- NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
- NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
- NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
- NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting
Other Cheng-Hsin General Hospital trials
Trials by the same sponsor.
- NCT07121283 — Artificial Intelligence Assisted Bone Age Assessment · NA · enrolling by invitation
- NCT07411703 — Automated Trainer-Based Gait Rehabilitation for Hemiplegic Stroke Patients · enrolling by invitation
- NCT06923514 — Health Literacy, Stress and Quality of Life in Heart Failure Patients · completed
- NCT06482372 — A Pilot Study of Repetitive Transcranial Magnetic Stimulation · NA · not yet recruiting
- NCT06978335 — Acupoint Stimulation Improves Postoperative Wound Pain · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06006819 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cheng-Hsin General Hospital
- Last refreshed: 23 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06006819.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing